Prostatype Genomics publishes Annual Report for 2019/20

Prostatype Genomics AB today publishes the Annual Report for the extended financial year of July 2019 to December 2020. The Annual Report is attached as a PDF and is available on the company's webpage: www.prostatypegenomics.com

About Prostatype Genomics

 

Prostatype Genomics AB manufactures, markets and sells the prognostic gene test
Prostatype®. By giving a assessment of the aggressiveness of the prostate cancer,
Prostatype® helps clinicians and patients to make correct treatment decisions.
Over and under treatment of prostate cancer can be minimized, the quality of life for
the patient improved and money can be saved for the health care sector.

This disclosure contains information that Prostatype Genomics AB is obliged to make public pursuant to the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 17-05-2021 09:00 CET.

Fredrik Persson

Media enquiries:
fredrik.persson@prostatypegenomics.com

Certified Advisor

Svensk Kapitalmarknadsgranskning AB, 011-32 30 732, ca@skmg.se

Subscribe